Novel factor XI inhibitors for postoperative VTE prophylaxis: Breakthroughs and insights from the ROXI-VTE-I and ROXI-VTE-II trials
-
-
REFERENCES
[1] Harrington J., Piccini J.P., Alexander J.H., et al. (2023). Clinical evaluation of factor XIa inhibitor drugs: JACC review topic of the week. J. Am. Coll. Cardiol. 81:771−779. DOI:10.1016/j.jacc.2022.11.057 [2] Weitz J.I., Kithcart A.P., O'Brien M.P., et al. (2025). Efficacy and safety of REGN9933(A2) and REGN7508(Cat) for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): Two randomised, open-label, phase 2 trials. Lancet 406:2551−2563. DOI:10.1016/s0140-6736(25)02097-5 [3] Verhamme P., Yi B.A., Segers A., et al. (2021). Abelacimab for prevention of venous thromboembolism. N. Engl. J. Med. 385:609−617. DOI:10.1056/NEJMoa2105872 [4] Connolly S.J., Crowther M., Eikelboom J.W., et al. (2019). Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N. Engl. J. Med. 380:1326−1335. DOI:10.1056/NEJMoa1814051 -
ABOUT THIS ARTICLE
Cite this article:
Xu J., Su Y. and Huang K. (2026). Novel factor XI inhibitors for postoperative VTE prophylaxis: Breakthroughs and insights from the ROXI-VTE-I and ROXI-VTE-II trials. The Innovation Medicine 4:100222. https://doi.org/10.59717/j.xinn-med.2026.100222
Welcome!
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Export File
Citation
Xu J., Su Y. and Huang K. (2026). Novel factor XI inhibitors for postoperative VTE prophylaxis: Breakthroughs and insights from the ROXI-VTE-I and ROXI-VTE-II trials. The Innovation Medicine 4:100222. https://doi.org/10.59717/j.xinn-med.2026.100222
Format
Content
DownLoad:
-
Figure 1.
Mechanism of action and clinical efficacy of two novel factor XI inhibitors for postoperative venous thromboembolism prophylaxis.
